Aduro BioTech (NASDAQ:ADRO) Downgraded by William Blair

Share on StockTwits

Aduro BioTech (NASDAQ:ADRO) was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, December 18th, Marketbeat reports.

NASDAQ:ADRO traded down $0.04 on Wednesday, hitting $1.15. 861,977 shares of the company’s stock were exchanged, compared to its average volume of 1,002,910. The firm has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.23. The company has a debt-to-equity ratio of 0.39, a current ratio of 7.26 and a quick ratio of 7.26. Aduro BioTech has a 52 week low of $0.90 and a 52 week high of $4.59. The company has a market cap of $95.81 million, a P/E ratio of -0.99 and a beta of 1.49.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.03. The company had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.55 million. Aduro BioTech had a negative net margin of 544.94% and a negative return on equity of 78.64%. On average, research analysts expect that Aduro BioTech will post -0.99 earnings per share for the current fiscal year.

In other news, insider Elsas Andrea Van sold 73,311 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.19, for a total value of $87,240.09. Following the sale, the insider now directly owns 445,190 shares of the company’s stock, valued at approximately $529,776.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 80,880 shares of company stock worth $96,020. 5.20% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of the company. Prudential Financial Inc. raised its holdings in Aduro BioTech by 31.4% in the 2nd quarter. Prudential Financial Inc. now owns 38,880 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 9,300 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Aduro BioTech by 3.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 306,081 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 11,164 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Aduro BioTech by 33.7% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 44,895 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 11,318 shares during the period. Northern Trust Corp raised its holdings in Aduro BioTech by 1.6% in the 2nd quarter. Northern Trust Corp now owns 759,916 shares of the biotechnology company’s stock valued at $1,171,000 after acquiring an additional 12,133 shares during the period. Finally, Swiss National Bank raised its holdings in Aduro BioTech by 21.4% in the 2nd quarter. Swiss National Bank now owns 89,000 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 15,700 shares during the period. 39.58% of the stock is currently owned by institutional investors.

Aduro BioTech Company Profile

Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.

Recommended Story: What is the market perform rating?

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.